Initiating or Switching Therapy in Multiple Sclerosis: New Evidence and Expert Insights

*US and Canadian HCPs*

Release Date: November 30, 2020

Expiration Date: November 30, 2021

Intended Audience:

Physicians and their teams providing care for patients with MS (PAs, NPs, nurses, pharmacists)

Accompanying this activity are resources to provide evidence-based guidance on necessary laboratory evaluations needed before initiating or switching DMTs, as well as a guide for evaluating treatment response and recognizing when a switch in therapy may be appropriate.

The expanding therapy landscape for multiple sclerosis (MS) includes multiple S1P-based disease-modifying therapies (DMTs) along with an abundance of data regarding their efficacy and safety, new requirements for pre-treatment testing and monitoring, and an enhanced need to engage patients in their care.

Tune into this webcast to hear leading MS experts share their perspectives on the latest advances in MS. Highlights include:

  • Key data on current and emerging MS therapies and the integration of this evidence into clinical practice
  • Case-based discussions and PDF tools that map out safe and effective navigation of DMT initiation and switching along with required assessments
  • Practical strategies to engage in shared decision-making and counsel patients on their treatment plans

Learning Objectives

  • Differentiate S1P-based disease-modifying therapies (DMTs) for multiple sclerosis (MS) based on clinical evidence for their safety, adherence potential, and efficacy, including clinical data on relapses, MRI lesions, brain volume loss, and disability progression
  • Apply evidence-based approaches for monitoring for insufficient response to therapy, disease worsening, and/or tolerability to support timely and appropriate testing and decision-making related to treatment escalation or switching
  • Employ leading principles, tools, and processes for engaging patients with MS and their caregivers in personalized shared decision-making on and adherence to MS treatment plans


  • Evaluating the Latest Clinical Data on S1P Receptor Modulators in Multiple Sclerosis
  • Case-Based Discussion: Safe and Effective DMT Switches and Required Assessments
    • User-Friendly Tools for Clinical Practice
  • Practical Strategies for Shared Decision-Making and Counseling Patients on Risks and Benefits of Different DMT Options Based on Current Evidence

This webinar is held in partnership with ACTRIMS and the The Canadian Network of MS clinics.


Allen C Bowling, MD, PhD
NeuroHealth Institute
Englewood, CO

Benjamin M Segal, MD
Chair, Department of Neurology
Director, Neuroscience Research Institute
Co-Director, Neurological Institute
Stanley D and Joan H Ross Chair in Neuromodulation
The Ohio State University College of Medicine
Columbus, OH

Erin Longbrake, MD, PhD
Assistant Professor of Neurology
Program Director, Multiple Sclerosis & Other Inflammatory Brain Disease Fellowship
Yale University School of Medicine
North Haven, CT

Virginia A Devonshire, MD
Contributing Author
Associate Clinical Professor, Division of Neurology
Fellowship Director, UBC Hospital Multiple Sclerosis Clinic
University of British Columbia
Vancouver, BC

Kristi Kay Orbaugh, RN, MSN, RNP, AOCN
Adult Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, IN

Mark A Rubin, MD
Medical Director
Fort Lauderdale, FL

Abimbola Farinde, PhD, PharmD
Peer Reviewer
Professor of Health Care Administration
Columbia Southern University College of Business
Orange Beach, AL

Joint Accreditation Statement

In support of improving patient care, PRIME® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Interprofessional Teams

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change.

Physician Credit Designation Statement

PRIME® designates this Live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistant Accreditation Statement

PRIME® has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioner Accreditation Statement

PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 1.0 contact hour (which includes 0.27 hour of pharmacology).

Pharmacist Accreditation Statement

This Application-based activity has been approved for 1.0 contact hour (0.1 CEUs) by PRIME® for pharmacists. The Universal Activity Number for this activity is JA0007144-0000-20-111-H01-P. Pharmacy CE credits will be submitted electronically to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service ([email protected]).

Nurse Accreditation Statement

PRIME® designates this activity for 1.0 contact hour.

Obtaining CE Credit

  1. Complete the pre-activity evaluation
  2. Complete the activity in its entirety
  3. Complete a post-activity evaluation
  4. Download and/or print a certificate of completion and/or submit CE credits electronically

Device Requirements

  • Computer, smartphone, tablet, or mobile device with audio capabilities and Internet connectivity

Faculty Disclosures

The following individuals have identified relevant financial relationships with commercial interests to disclose:

  • Allen C Bowling, MD, PhD (Speaker)
    Advisory Board or Panel – Bristol Myers SquibbGreenwich BiosciencesNeuroHealth Institute
    Consultant – Greenwich Biosciences
    Speakers Bureau or other Promotional Education – Bristol Myers SquibbNeuroHealth Institute
  • Erin Longbrake, MD, PhD (Moderator)
    Advisory Board or Panel – AlexionGenentechGenzyme
    Grants / Research Support – Genentech
  • Virginia A Devonshire, MD (Contributing Author)
    Advisory Board or Panel – BiogenNovartisrochesanofi-genzyme
    Consultant – BiogenNovartisrochesanofi-genzyme
    Speakers Bureau or other Promotional Education – BiogenNovartisalexionrochesanofi-genzyme

The following individuals have no relevant financial relationships with commercial interests to disclose:

  • Benjamin M Segal, MD (Speaker)
  • Abimbola Farinde, PhD, PharmD (Reviewer)
  • Kristi Kay Orbaugh, RN, MSN, RNP, AOCN (Planner)
  • Mark A Rubin, MD (Planner)

All PRIME staff participating in planning and content development have no relevant financial relationships with commercial interests to disclose.

Funding Disclosure

This activity is provided by PRIME Education. There is no fee to participate. This activity is supported by an educational grant from Bristol-Myers Squibb.

Accessibility Statement

At PRIME, we are committed to ensuring that individuals with disabilities can access all of the content offered by PRIME through our website and other properties. If you are having trouble accessing, please email [email protected] for assistance. Please put “ADA Inquiry” in the subject line of your email.

About Me

The Continuing Medical Education Program is an integral part of the organization’s overall mission which aims to improve learners’ competence and performance‐in‐practice and ultimately improve patient outcomes.

Related Posts